Remicade - Biotech Research

This report investigates three goals in optimizing product potential- expanding the drug's patent protected lifespan, accessing broader patient populations and launching line-extensions via fixed dose combinations. The key success factors in each of these pursuits have been clearly identified, emerging trends have ...

Schering-Plough profit jumps 49 percent as drugmaker records lower 1-time itemsDrugmaker Schering-Plough Corp. on Tuesday reported reduced second-quarter sales mainly due to the strong dollar, but its profit still jumped 49 percent, thanks to much lower one-time charges than a year ago. ...

Schering-Plough Corporation (SGP) Q4 2008 Earnings Call February 03, 2009 8:00 am ET. This morning, I am joined by Fred Hassan, our Chairman and Chief Executive Officer; Rob Bertolini, our Chief Financial Officer and Carrie Cox, the Head of our Global Pharmaceuticals. ...

Schering-Plough (SGP) is expected to report Q3 earnings Tuesday Oct. 21 before market open, with a conference call scheduled for 8:00 am ET. The consensus range is 29c to 34c for EPS, and revenue of $3.95B to $4.67B, according to First Call. ...

Topic: Remicade

Optimizing Lifecycle Management: Maximizing Commercial Lifespan Through Label Expansion And Combination Products

The Future Of Clean Thermal Technologies: Technology Developments, Key Costs And The Future Outlook-Aarkstore Enterprise

The Future Of Virtualization: Emerging Trends And The Evolving Vendor Landscape-Aarkstore Enterprise

Schering-Plough 2nd-quarter profit jumps

Schering-Plough Q4 2008 Earnings Call Transcript

Earnings Preview: Schering-Plough

From Around the Web

Video Gallery

Follow this Topic with...